Please try another search
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Name | Age | Since | Title |
---|---|---|---|
David G. Elsley | - | 2017 | President, CEO & Director |
Guillermo Torre-Amione | - | 2018 | Independent Chairman |
Peter Pekos | - | 2017 | Independent Director |
Christopher J. Waddick | - | 2018 | CFO, Corporate Secretary & Director |
Colin G. Stott | 58 | 2019 | Independent Director |
Bruce McManus | - | 2022 | Member of Scientific Advisory Board |
Paul M. Ridker | - | 2022 | Member of Scientific Advisory Board |
Michael Jay Willner | 66 | 2021 | Independent Director |
Joseph A. Hill | - | 2022 | Member of Scientific Advisory Board |
Teri Loxam | 51 | 2022 | Independent Director |
Jennifer M. Chao | 54 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review